从治疗致命疾病的药品到止痛药和抗组胺药等价格低廉的非专利药品，各种药物都有造假的情况出现。
All kinds of medicines have been counterfeited, from medicines for the treatment of life-threatening conditions to inexpensive generic versions of painkillers and antihistamines.
这些非专利药品和专利药完全一样，只是没有品牌名称，也就是不向医药公司支付巨额专利费。
They are the exact same product, but without the brand name — or the fat patent payments to drug companies.
无品牌非专利药会使药品竞争异常激烈，以美国为例，某专利药在保护期到期后的一年内其价格降幅会超过85%。
Where competition from unbranded generics is fiercest, for instance in America, the price of a given drug falls by more than 85% within a year of patent expiry.
在私立部门，非专利药品的价格比国家参考价格平均高出六倍以上。一般来说，专利品牌药会更加昂贵。
In the private sector, generic medicines cost on average six times more than their international reference price, while originator brands are generally even more expensive.
对已成型的制药业来说，最好的方法就是找到许多新的畅销药来取代专利将要过期的药品。
The best way out for the established drugs industry would be to find lots of clever new blockbusters to replace the ones going off-patent.
目前的核心仍然在非专利品牌药品市场，因为担心市场上没牌子的药是假药或者质量不可靠，所以人们纷纷购买品牌药，这使得品牌药在许多新兴市场的需求增大。
The real action now is in branded generics, which command a premium in many emerging markets due in part to the fear that unknown products might be fake or of dubious quality.
我们通过热忱地保护美国医药公司的专利，却阻碍了像巴西这样的国家生产未注册的治疗艾滋的药品的能力，这些药也许能够挽救百万的生命。
In our zeal to protect the patents of American drug companies, we've discouraged the ability of countries like Brazil to produce generic AIDS drugs that could save millions of lives.
中国的政策支持会更进一步降低仿制药的价格，这会给药品研发机构及国际非专利药公司带来深远影响。
Chinese policy will drive generic prices down still further, with far-reaching consequences for both R&D players and international generic companies.
由于大型制药公司的重点产品许多面临专利过期，患者纷纷转向非专利药，这些公司还面临要不断开发新药品的任务。
The big pharmaceutical companies are also struggling to refill their product pipelines with new offerings as their blockbuster drugs' patents expire and patients switch to generics.
由于大型制药公司的重点产品许多面临专利过期，患者纷纷转向非专利药，这些公司还面临要不断开发新药品的任务。
The big pharmaceutical companies are also struggling to refill their product pipelines with new offerings as their blockbuster drugs' patents expire and patients switch to generics.
应用推荐